MITIGATE shares latest results at RöKo 2017
MITIGATE was recently present at the German Röntgen Congress 2017 in Leipzig, Germany. The latest results and information were shared at a dedicated project booth during the congress exhibition. Furthermore, MITIGATE organised a workshop where the project’s innovations which are ready for, or close to, the market were introduced. Project results were also introduced and discussed by MITIGATE partners during a Highlight Session on GIST.
The German Röntgen Congress is the annual congress of the German Society of Radiology and attrachts approximately 7,000 visitors each year.
Innovation Workshop at German Röntgen Conress
MITIGATE will host its Innovation Workshop at the German Röntgen Congress 2017 on May 26th from 10:00-12:00. Here, the consortium will present innovations for diagnostic imaging and minimally invasive treatment which are ready for the market.
Additionally, MITIGATE will also have an exhibition booth with additional information about the project and its results and achievements.
The programme of the Innovation Workshop can be seen below:
Start of patient recruitment for MITIGATE clinical study
MITIGATE is recruiting patients with metastatic GIST who are experiencing tumour progression while under treatment with Imatinib (Glivec®, Gleevec™) for a diagnostic clinical study.
MITIGATE uses an innovative imaging approach focusing on progressive tumour lesions. While the approach is diagnostic rather than therapeutic, patients may derive real benefits from the new imaging procedure, such as improved tumour volume definition and better detection of disease.
European patients with metastatic GIST can fill out the enrolment questionnaire to determine whether you meet the requirements for participation in our study. You access the questionnaire by clicking here.
MITIGATE newsletter – 3rd edition
In the third newsletter, MITIGATE presents achievements & upcoming activities regarding the first-in-human application of the diagnostic tracer developed during the project.
MITIGATE newsletter – 3rd edition
3rd IRDiRC Conference, February 8-9 in Paris, France
Save the date for the third International Rare Diseases Research Consortium conference in Paris, France
The third conference of the International Rare Diseases Research Consortium (IRDiRC) will take place February 8-9, 2017 in Paris, France at the conference center of Université Pierre et Marie Curie Jussieu.
Since it’s launch in 2011, IRDiRC has made considerable advances in rare diseases research. This conference presents a unique opportunity to reflect upon the progress made, confront barriers, and form new collaborations to take on challenges posed by rare diseases.
All stakeholders – active investigators, policy makers, young researchers and patient advocates alike – active in the area of rare diseases from across the globe are invited to join the IRDiRC conference to celebrate achievements in the field, identify future milestones and goals, and work toward bringing diagnoses and therapies to all rare disease patients.
More information on the IRDiRC is available on the website: www.irdirc.org
Last chance to participate in the End-User survey
You are still able to help us assess the community’s interest in MITIGATE’s innovative results!
In order to successfully exploit the project’s developments, and support us in bringing products to the European patients, we kindly ask you to participate in the MITIGATE End-User survey.
You can access the survey here
MITIGATE session at ECR 2016
The MITIGATE consortium organised a session on clinical trials in interventional radiology on the occasion of the European Congress of Radiology 2016 in Vienna. The session “MITIGATE what does it take to perform clinical trials in interventional radiology?” attracted a significant number of attendees, and discussion on setting up and running trials in interventional radiology.
Speakers and moderators, Prof. Dr. Werner Jaschke and Prof. Dr. Stefan Schönberg, were pleased to see a high interest among radiologists in the presented topics.
Click here to get more information about the session and to watch it online*
*Please note that users must register online in order to watch sessions from the ECR
MITIGATE End-User Survey
We’re pleased to announce that today the MITIGATE End-User Survey was launched.
The aim of this survey is to assess how you, the community, might want to exploit MITIGATE’s innovative results. We kindly ask you to participate in the survey and support us in bringing the MITIGATE products to the European patient.
The survey can be accessed here: http://www.mitigate-project.eu/category-2/cat2-sub5/mitigate-end-user-survey.
Minimally invastive treatment folder for patients
To highlight the treatment options on the horizon for GIST patients, MITIGATE published a small folder detailing the project’s developments in percutaneous ablation and selective internal radiation therapy. MITIGATE is developing several new treatment options for GIST, including minimally invasive surgery.
You can view the MITIGATE Minimally Invasive Treatment folder for patients here.
Feel free to contact EIBIR at email@example.com if you would like to receive printed folders for distribution among GIST patients at your institution.
Annual Meeting of General Assembly
On September 25th, MITIGATE partners held their annual meeting of the General Assembly hosted by partner AAA in Marseille, FR. Participants presented achievements of the last months as well as an outlook on major tasks ahead.
Furthermore, the pivotal questions of the selection of tracers, in-human studies and plans for exploitation of results were discussed. We are pleased to announce that after the meeting the consortium has agreed on a promising work plan for the coming year and together will work towards innovation, clinical Implementation and exploitation of the project`s objectives.